DU
PTGX icon

Delphia (USA)’s Protagonist Therapeutics PTGX Stock Holding History

Delphia (USA)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,845
Closed -$94K – 393
2022
Q2 		$94K Buy
+11,845
New +$143K 0.06% 342

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Delphia (USA)'s PTGX Position: Q3 2022 in Review

Delphia (USA) sold out of Protagonist Therapeutics (PTGX) in Q3 2022, closing a stake of 11,845 shares — an estimated $94K sold.

Delphia (USA) first reported a position in PTGX in Q2 2022 and held it in 1 quarter. The position peaked at $94K in Q2 2022. 130 funds tracked by Wall St. Rank hold PTGX as of Q3 2022.

  • Delphia (USA) reported no remaining Protagonist Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Delphia (USA) sold 11,845 Protagonist Therapeutics shares in Q3 2022, an estimated $94K.
  • Delphia (USA) first reported a position in Protagonist Therapeutics in Q2 2022 and held it in 1 quarter.
  • Delphia (USA)'s Protagonist Therapeutics position peaked at $94K in Q2 2022.
  • 130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.